Induction of multi-functional T cells in a phase I clinical trial of dendritic cell immunotherapy in hepatitis C virus infected individuals

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Li, Shuo ^a,b   Roberts, Stuart ^c   Plebanski, Magdalena ^b   Gouillou, Maelenn ^a   Spelman, Tim ^a,b   Latour, Philippe ^a   Jackson, David ^d   Brown, Lorena ^d   Sparrow, Rosemary L ^b,e   Prince, H Miles ^d   Hart, Derek ^f   Loveland, Bruce E ^a,b   Gowans, Eric J ^a,b,g  

^a BURNET INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; TRANSCRIPTION FACTOR FOXP3; VIRUS ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; DENDRITIC CELL; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; HEPATITIS C; HUMAN; IN VIVO STUDY; LYMPHOCYTE FUNCTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; REGULATORY T LYMPHOCYTE;

ADULT; ANTIGENS, CD3; ANTIGENS, VIRAL; CYTOKINES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LIPOPEPTIDES; MALE; MIDDLE AGED; MONOCYTES; T-LYMPHOCYTES; TISSUE THERAPY;

EID: 84865057153     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039368     Document Type: Article

References (18)

1. Gowans EJ, Roberts S, Jones K, Dinatale I, Latour PA, et al. ((2010)) A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol 53:: 599--607.
2. Jones KL, Brown LE, Eriksson EM, Ffrench RA, Latour PA, et al. ((2008)) Human dendritic cells pulsed with specific lipopeptides stimulate autologous antigen-specific T cells without the addition of exogenous maturation factors. J Viral Hepat 15:: 761--772.
3. Seder RA, Darrah PA, Roederer M, ((2008)) T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8:: 247--258.
4. Ahmed R, Akondy RS, ((2011)) Insights into human CD8(+) T-cell memory using the yellow fever and smallpox vaccines. Immunol Cell Biol 89:: 340--345.
5. Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, et al. ((2002)) A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 260:: 157--172.
6. Lamoreaux L, Roederer M, Koup R, ((2006)) Intracellular cytokine optimization and standard operating procedure. Nat Protoc 1:: 1507--1516.
7. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. ((2006)) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107:: 4781--4789.
8. Li S, Floess S, Hamann A, Gaudieri S, Lucas A, et al. ((2009)) Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection. PLoS Pathog 5:: e1000707.
9. Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR, ((2007)) Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 81:: 8468--8476.
10. Li S, Jones KL, Woollard DJ, Dromey J, Paukovics G, et al. ((2007)) Defining target antigens for CD25+ FOXP3+IFN-gamma- regulatory T cells in chronic hepatitis C virus infection. Immunol Cell Biol 85:: 197--204.
11. Li S, Gowans EJ, Chougnet C, Plebanski M, Dittmer U, ((2008)) Natural regulatory T cells and persistent viral infection. J Virol 82:: 21--30.
12. Banerjee DK, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar KM, ((2006)) Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 108:: 2655--2661.
13. Zou W, ((2006)) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:: 295--307.
14. Housley WJ, Adams CO, Nichols FC, Puddington L, Lingenheld EG, et al. ((2011)) Natural but not inducible regulatory T cells require TNF-alpha signaling for in vivo function. J Immunol 186:: 6779--6787.
15. Chen X, Oppenheim JJ, ((2010)) TNF-alpha: an activator of CD4+FoxP3+TNFR2+ regulatory T cells. Curr Dir Autoimmun 11:: 119--134.
16. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, et al. ((2006)) TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 108:: 253--261.
17. Zanin-Zhorov A, Ding Y, Kumari S, Attur M, Hippen KL, et al. ((2010)) Protein kinase C-theta mediates negative feedback on regulatory T cell function. Science 328:: 372--376.
18. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, et al. ((2007)) Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 19:: 345--354.